- BIN# 004682
- PCN# CN
- GRP# EC57029004
- ID# 414639234866
Would you like to receive the saving card details via email?
GO MOBILE to use Apple Wallet or Google pay to add Savings card to add the savings card to Apple Wallet or Google Pay
For care beyond your prescription.
Breathing Room was created to help give you room to breathe.
Step inside to your breathing destination, and let us connect you to the services and support that can help with your treatment and beyond. Open up possibilities, connect with others, and let us help you focus on what really matters—your breathing.
Pharmacist Instructions for a Patient With an Eligible Third-Party Payer:
Program managed by ConnectiveRx, on behalf of AstraZeneca.
People with asthma who take long-acting beta2-adrenergic agonist (LABA) medicines, such as formoterol fumarate (one of the medicines in BEVESPI AEROSPHERE), have an increased risk of death from asthma problems. It is not known if LABA medicines increase the risk of death in people with COPD. BEVESPI AEROSPHERE is only approved for use in COPD. BEVESPI AEROSPHERE is not approved for use in asthma.
- Call your healthcare provider if breathing problems worsen over time while using BEVESPI AEROSPHERE
- Get emergency medical care if your breathing problems worsen quickly or if you use your rescue inhaler, but it does not relieve your breathing problems
- Do not use BEVESPI AEROSPHERE to treat sudden symptoms of COPD. Always have a rescue inhaler with you to treat sudden symptoms
- BEVESPI AEROSPHERE is not for the treatment of asthma. It is not known if BEVESPI AEROSPHERE is safe and effective in people with asthma
- Do not use BEVESPI AEROSPHERE if you are allergic to glycopyrrolate, formoterol fumarate, or to any of the ingredients in BEVESPI AEROSPHERE
- Do not use BEVESPI AEROSPHERE more often than prescribed
- Do not take BEVESPI AEROSPHERE with other medicines that contain a LABA or an anticholinergic for any reason. Tell your healthcare provider about all the medicines you take
- Tell your healthcare provider about all your medical conditions including heart problems, high blood pressure, seizures, thyroid problems, diabetes, liver problems, glaucoma, prostate or bladder problems, or problems passing urine
BEVESPI AEROSPHERE can cause serious side effects, including:
- Sudden breathing problems immediately after inhaling your medicine
- Serious allergic reactions. Call your healthcare provider or get emergency medical care if you get any of the following symptoms of a serious allergic reaction: rash; hives; swelling of the face, mouth and tongue; breathing problems
- Fast or irregular heartbeat, increased blood pressure, chest pain
- Tremor or nervousness
- New or worsened eye problems, including acute narrow-angle glaucoma. Symptoms may include: eye pain or discomfort, nausea or vomiting, blurred vision, seeing halos or bright colors around lights, and red eyes. If you have these symptoms, call your healthcare provider right away before taking another dose
- New or worsened urinary retention. Symptoms may include difficulty urinating, painful urination, urinating frequently, or urinating in a weak stream or drips. If you have any of these symptoms, stop taking BEVESPI AEROSPHERE and call your healthcare provider right away
- High blood sugar or low blood potassium
Common side effects of BEVESPI AEROSPHERE include urinary tract infection and cough. Tell your healthcare provider about any side effect that bothers you or that does not go away.
BEVESPI AEROSPHERE is a prescription medicine used to treat chronic obstructive pulmonary disease (COPD). COPD includes chronic bronchitis, emphysema, or both. BEVESPI AEROSPHERE is used long term as 2 inhalations, 2 times each day in the morning and in the evening, to improve symptoms of COPD for better breathing. Do not use BEVESPI AEROSPHERE to treat sudden symptoms of COPD; it won't replace a rescue inhaler. BEVESPI AEROSPHERE is not for the treatment of asthma.
People with asthma who take long-acting beta2-adrenergic agonist (LABA) medicines, such as formoterol fumarate (one of the medicines in BEVESPI AEROSPHERE), have an increased risk of death from asthma problems. It is not known if LABA medicines increase the risk of death in people with COPD.